MNKD

+ Watchlist + Portfolio

MannKind Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.40
52-Week Range: $2.23 – $6.51
Market Cap: $1.36B
P/E (TTM): —
EPS (TTM): -0.15
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: 4.39
Return on Equity: —
Return on Assets: 0.79%
Gross Margin: 75.39%
Operating Margin: -0.76%
Profit Margin: -11.08%
Current Ratio: 1.72
Debt/Equity: —
Total Debt: $433.83M
Free Cash Flow: $40.31M
Revenue Growth: 42.90%
Earnings Growth: —
Enterprise Value: $1.69B

MNKD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$99.77M	$198.96M	$285.50M	$348.97M
Cost of Revenue	$57.50M	$62.77M	$76.60M	$87.96M
Gross Profit	$42.27M	$136.19M	$208.90M	$261.01M
Research & Development	$19.72M	$31.28M	$45.89M	$66.35M
Selling, General & Admin	$91.47M	$94.31M	$94.33M	$144.13M
Operating Expenses	$111.19M	$125.60M	$140.22M	$214.46M
Operating Income	-$68.92M	$10.59M	$68.68M	$46.55M
EBITDA	-$56.32M	$19.11M	$75.66M	$51.51M
Pretax Income	-$87.40M	-$10.38M	$30.52M	$1.41M
Income Tax	$0.00	$1.56M	$2.93M	-$4.46M
Net Income	-$87.40M	-$11.94M	$27.59M	$5.86M
Diluted EPS	-0.34	-0.04	0.10	0.02
Diluted Shares	257.09M	267.01M	283.84M	314.11M

MNKD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$69.77M	$238.48M	$46.34M	$74.88M
Receivables	$16.80M	$14.90M	$11.80M	$38.37M
Inventory	$21.77M	$28.55M	$27.89M	$35.31M
Current Assets	$234.90M	$373.39M	$268.31M	$291.58M
Total Assets	$295.28M	$475.20M	$393.84M	$792.18M
Current Liabilities	$67.30M	$104.13M	$81.84M	$171.03M
Long-Term Debt	$273.49M	$248.70M	$36.05M	$318.36M
Total Debt	$278.83M	$272.62M	$50.12M	$367.44M
Total Liabilities	$545.82M	$721.37M	$472.66M	$843.20M
Retained Earnings	-$3.22B	-$3.23B	-$3.20B	-$3.20B
Shareholders' Equity	-$250.54M	-$246.17M	-$78.82M	-$51.02M
Working Capital	$167.60M	$269.27M	$186.47M	$120.55M
Net Debt	$203.72M	$30.22M	—	$279.76M

MNKD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$80.68M	$34.09M	$42.51M	$18.25M
Capital Expenditure	-$7.59M	-$42.44M	-$9.69M	-$4.57M
Free Cash Flow	-$88.27M	-$8.35M	$32.82M	$13.69M
Depreciation & Amortisation	$6.31M	$4.54M	$7.37M	$12.28M
Stock-Based Compensation	$13.45M	$17.65M	$21.36M	$24.20M
Investing Cash Flow	$4.87M	-$1.99M	-$96.65M	-$304.80M
Financing Cash Flow	$21.39M	$136.61M	-$137.27M	$315.10M
Net Change in Cash	-$54.42M	$168.71M	-$191.40M	$28.55M

MNKD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$78.35M	$76.53M	$82.13M	$111.95M	$90.17M
Cost of Revenue	$17.52M	$20.57M	$20.20M	$29.67M	$17.47M
Gross Profit	$60.84M	$55.96M	$61.93M	$82.28M	$72.70M
Research & Development	$11.02M	$13.68M	$14.06M	$27.59M	$17.23M
Selling, General & Admin	$25.01M	$31.62M	$29.09M	$58.41M	$54.09M
Operating Expenses	$36.04M	$45.30M	$43.15M	$89.97M	$75.68M
Operating Income	$24.80M	$10.66M	$18.78M	-$7.69M	-$2.98M
EBITDA	$26.85M	$9.75M	$17.92M	-$3.05M	$2.93M
Pretax Income	$13.62M	$940.00K	$7.78M	-$20.93M	-$16.37M
Income Tax	$459.00K	$272.00K	-$204.00K	-$4.98M	$253.00K
Net Income	$13.16M	$668.00K	$7.99M	-$15.95M	-$16.62M
Diluted EPS	0.04	0.00	0.03	-0.05	-0.05
Diluted Shares	320.90M	311.48M	311.64M	307.26M	308.27M

MNKD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$47.31M	$57.01M	$127.39M	$74.88M	$52.83M
Receivables	$28.90M	$27.14M	$17.38M	$38.37M	$28.14M
Inventory	$28.89M	$28.49M	$26.97M	$35.31M	$49.17M
Current Assets	$273.74M	$279.03M	$358.84M	$291.58M	$251.16M
Total Assets	$410.14M	$411.70M	$494.64M	$792.18M	$744.40M
Current Liabilities	$115.94M	$111.83M	$109.13M	$171.03M	$134.56M
Long-Term Debt	—	—	$73.43M	$318.36M	$318.72M
Total Debt	$47.25M	$46.82M	$119.91M	$367.44M	$330.96M
Total Liabilities	$468.76M	$466.74M	$539.19M	$843.20M	$803.60M
Retained Earnings	-$3.19B	-$3.19B	-$3.18B	-$3.20B	-$3.21B
Shareholders' Equity	-$58.62M	-$55.04M	-$44.55M	-$51.02M	-$59.20M
Working Capital	$157.80M	$167.20M	$249.71M	$120.55M	$116.60M
Net Debt	—	—	—	$279.76M	$265.89M

MNKD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$6.38M	$8.95M	$23.64M	-$7.96M	-$5.37M
Capital Expenditure	-$330.00K	-$1.12M	-$1.13M	-$1.99M	-$1.88M
Free Cash Flow	-$6.71M	$7.83M	$22.52M	-$9.95M	-$7.25M
Depreciation & Amortisation	$2.65M	$2.62M	$2.80M	$4.21M	$6.91M
Stock-Based Compensation	$5.38M	$7.52M	$4.32M	$6.97M	$6.46M
Investing Cash Flow	$5.96M	$6.26M	-$25.06M	-$291.96M	$18.73M
Financing Cash Flow	$1.39M	-$5.51M	$71.81M	$247.41M	-$35.41M
Net Change in Cash	$975.00K	$9.70M	$70.39M	-$52.51M	-$22.05M

Market Snapshot

About

MannKind develops and commercializes Afrezza, an inhaled insulin therapy for adults with diabetes. The biopharmaceutical company focuses on Technosphere drug delivery technology for pulmonary administration of therapeutic compounds.